Immuno-Biological Laboratories Co., Ltd.
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Immuno-Biological Laboratories Co., Ltd. owes ¥0.14 for every ¥1 it owns. Net profit rose 32% in the year to Mar 2026.
Compared with Healthcare companies in Japan · latest annual results Mar 2026.
P/E ratio
26.1Investors pay ¥26.1 for every ¥1 of Immuno-Biological Laboratories Co., Ltd.'s yearly profit, higher than 77% of Healthcare companies in Japan.
P/B ratio
5.21The share price is 5.21 times Immuno-Biological Laboratories Co., Ltd.'s book value per share, higher than 88% of Healthcare companies in Japan.
Market cap
¥9.6 BThe total market value of all of Immuno-Biological Laboratories Co., Ltd.'s shares at today's price (share price × number of shares), smaller than 61% of Healthcare companies in Japan. PosiCap size class: Micro Cap.
Net worth (book value)
¥1.8 BWhat Immuno-Biological Laboratories Co., Ltd. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
¥197.93Net worth divided by the number of shares. The share price of ¥1,032 is 5.2 times this, which is the P/B above.
Return on equity (ROE)
21.3%Immuno-Biological Laboratories Co., Ltd. earned 21.3% on its shareholders' money over the last year, higher than 91% of Healthcare companies in Japan.
Owes vs Owns
0.14×Immuno-Biological Laboratories Co., Ltd. owes ¥0.14 for every ¥1 it owns (low), lower than 86% of Healthcare companies in Japan.
Dividend yield
0.74%Immuno-Biological Laboratories Co., Ltd. pays 0.74% of its share price as dividends a year, lower than 98% of dividend-paying Healthcare companies in Japan.
Revenue growth
+4%Revenue rose 4% in the year to Mar 2026, and grew 8% a year on average over 3 years.
Profit growth
+32%Net profit rose 32% in the year to Mar 2026.
Profit margin
32.7%Immuno-Biological Laboratories Co., Ltd. keeps ¥33 of every ¥100 of revenue as net profit.
Cash quality
0.92×Cash from Immuno-Biological Laboratories Co., Ltd.'s business was 0.92× its reported profit in the year to Mar 2026 — less cash came in than the profit reported.
Interest cover
211.0×Immuno-Biological Laboratories Co., Ltd.'s operating profit covered its interest costs 211.0 times in the year to Mar 2026.
Cash vs debt
Net cashImmuno-Biological Laboratories Co., Ltd. held ¥812 M more cash than debt (net cash) at Mar 2026.
Questions
What is Immuno-Biological Laboratories Co., Ltd.'s P/E ratio?
Investors pay ¥26.1 for every ¥1 of Immuno-Biological Laboratories Co., Ltd.'s yearly profit, higher than 77% of Healthcare companies in Japan.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Immuno-Biological Laboratories Co., Ltd.: ¥9.6 B ÷ ¥1.8 B (31 Mar 2026) = 5.2.
What is Immuno-Biological Laboratories Co., Ltd.'s return on equity?
Immuno-Biological Laboratories Co., Ltd. earned 21.3% on its shareholders' money over the last year, higher than 91% of Healthcare companies in Japan.
How much does Immuno-Biological Laboratories Co., Ltd. owe compared with what it owns?
Immuno-Biological Laboratories Co., Ltd. owes ¥0.14 for every ¥1 it owns (low), lower than 86% of Healthcare companies in Japan.
Does Immuno-Biological Laboratories Co., Ltd. pay a dividend?
Yes. Immuno-Biological Laboratories Co., Ltd. pays 0.74% of its share price as dividends a year, lower than 98% of dividend-paying Healthcare companies in Japan.
Is Immuno-Biological Laboratories Co., Ltd.'s revenue growing?
Revenue rose 4% in the year to Mar 2026, and grew 8% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.